secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001104659-23-118166
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconova Q3 net loss $4.7M; cash $25.2M; narazaciclib dose escalation extended into Q1 2024
--------------------------------------------------------------------------------

- Net loss Q3 2023: $4.7M ($0.23/sh) vs $5.4M ($0.26/sh) year ago; cash $25.2M sufficient into Q3 2024.
- Narazaciclib Phase 1/2 dose escalation extended to at least one more cohort; no significant neutropenia or diarrhea.
- Rigosertib registrational trial plan update for RDEB-associated SCC expected in first half of 2024.
- Preclinical data for narazaciclib to be presented at SABCS and ASH in December 2023.
- Appointed Dr. Victor Moyo as CMO and Meena Arora as VP Medical Affairs in Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465923118166/0001104659-23-118166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465923118166/tm2330724d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-118166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer